In 2023, Australia became the first country in the world to legalise MDMA and psilocybin for psychiatric treatment. This decision marks a major shift in the way mental health disorders like PTSD and treatment-resistant depression are addressed. While the U.S. FDA rejected MDMA-assisted therapy in 2024, other countries are pushing forward with psychedelic research. What does this mean for global mental health, and why is Australia leading the charge?

What’s Changing in MDMA & Psilocybin Therapy?
As of July 2023, Australian psychiatrists can prescribe MDMA for post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression. This decision by Australia’s Therapeutic Goods Administration (TGA) was initially met with skepticism but was ultimately influenced by over 3,000 public submissions advocating for the change.
According to Mind Medicine Australia (MMA), 1 in 4 Australians suffer from mental health disorders, yet there have been no significant breakthroughs in psychiatric treatments for over 50 years. Clinical trials published in the New England Journal of Medicine show that MDMA-assisted therapy can reduce PTSD symptoms by over 60%, while studies from Johns Hopkins University indicate psilocybin therapy can provide lasting relief for major depressive disorder.
The U.S. FDA Rejection
Despite research from MAPS (Multidisciplinary Association for Psychedelic Studies), the U.S. FDA rejected MDMA-assisted therapy in 2024, citing concerns over study methodologies and possible misuse. This decision disappointed mental health advocates, especially veterans who have seen significant improvements through MDMA treatment. However, individual states like Oregon and Colorado have taken steps to decriminalise or regulate psychedelics for medical use.
Global Psychedelic Advances
Australia isn’t alone in exploring the potential of psychedelics. Here’s how other countries are advancing psychedelic medicine:
🇨🇦 Canada: Special exemptions allow psilocybin therapy for end-of-life distress, and Health Canada has expanded research on MDMA.
🇨🇭 Switzerland: Has permitted LSD and MDMA therapy since 2014 under strict clinical supervision, with ongoing trials at the University of Basel.
🇮🇱 Israel: Running MDMA trials for PTSD, particularly for military veterans, supported by Sheba Medical Center.
🇳🇱 Netherlands: Legal “truffle” retreats offer psilocybin therapy outside of medical settings, drawing thousands of participants yearly.
🇬🇧 UK: Researchers from Imperial College London continue to push for the rescheduling of psychedelics to enable broader psychiatric use.
Challenges
Despite legalisation, access to psychedelic therapy remains expensive and highly regulated in Australia. A nine-month MDMA-assisted therapy course costs AU$27,000 (~$16,500 USD), making it inaccessible to many. Similarly, while medical marijuana is legal, 78% of Australians still turn to the black market due to high costs.
To address these concerns, organisations like MMA are pushing for insurance coverage and government funding, particularly for veterans and first responders with PTSD. The Department of Veterans’ Affairs is expected to review funding applications for psychedelic therapy by March 2025.
The Future of Psychedelic Medicine
The acceptance of psychedelics as mental health treatments is gaining momentum worldwide. As Australia sets a precedent, more countries may follow suit. While regulatory hurdles remain, ongoing research and advocacy continue to push psychedelics into mainstream psychiatric treatment.
With the global mental health crisis worsening, the potential of psychedelics could offer lifesaving relief—if policy evolves responsibly. The world is watching Australia. Will other nations be next?
References:
Mind Medicine Australia: www.mindmedicineaustralia.org
New England Journal of Medicine: "MDMA for PTSD – A Breakthrough Study" (2023)
Johns Hopkins Center for Psychedelic & Consciousness Research: "Psilocybin and Depression" (2023)
MAPS: www.maps.org
Imperial College London Psychedelic Research: www.imperial.ac.uk/psychedelic-research
Comments